Most comparative trials compared tirzepatide against semaglutide at a dose of 1 mg, and head-to-head evaluations with higher doses of semaglutide 2.4 mg (approved for obesity), or with other oral GLP-1 agents are currently lacking. Here, GLP1R is linked to obesity disorder.